Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.
about
Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhoodAntiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhoodNeurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adultsDrug insight: New antiemetics in the management of chemotherapy-induced nausea and vomitingUpdate and new trends in antiemetic therapy: the continuing need for novel therapies.Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomitingAprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting.5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial.Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.Predicting infectious complications in neutropenic children and young people with cancer (IPD protocol).Update on anti-emetics for chemotherapy-induced emesis.Emerging drugs for chemotherapy-induced emesis.The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy.Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain.Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.Hepatitis B virus reactivation associated with anti-neoplastic therapy.Patient- and treatment-related risk factors for nausea and emesis during concurrent chemoradiotherapy.Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting.Efficacy of palonosetron and ramosetron on postoperative nausea and vomiting related to intravenous patient-controlled analgesia with opioids after gynecological laparoscopic surgery (double-blinded prospective randomized controlled trial).A qualitative study investigating chemotherapy-induced nausea as a symptom cluster.QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist.A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer.Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
P2860
Q24186174-8BCBDBEA-1109-427B-B731-301E4BAF138EQ24235502-C6C62299-F18C-4298-8896-D1DB70834857Q24243745-C1245234-B80D-4B97-B799-5379F6E8809DQ28280032-0CE040C6-C96C-421F-B72E-C721871049A7Q34143667-AF28B8FC-AE24-4969-BC5D-2994CFC05F5AQ34239808-052B8790-2638-4FC6-A692-5640F822E461Q34450534-F2B7DF94-C755-4B37-9EA1-09979229F5D3Q35146420-7C826EC8-9B9C-47E0-900D-BC4356491F09Q35871611-AC0ABDAD-8B99-4BA9-8C6D-30C8A32578E5Q35958125-513A3979-06A0-4BFE-98CA-26359B6E4AFFQ36263659-86C5848C-0CEC-4A8A-8680-B7F903F18006Q36407422-513BD46A-56EA-40A8-8E5F-CAA09C50BC6BQ36548740-EFAAF1CD-14FD-43C5-BD30-27825089E140Q36639416-3AC90B61-FEB0-4D4F-84CA-59BD892BCA0CQ37038999-F9E5DF8A-6755-4D06-8878-F2C3301F08D4Q37355479-046177A4-5CEB-4D98-BF26-9EB2A6C64F9FQ37387345-F8B2E5A1-0C34-4EF8-9629-9FD21C61B924Q37551843-E8C03044-E40C-4B52-AB76-9DD724BEE642Q38047362-21B0C446-7D8A-4C44-BF0C-118F345B764BQ39793779-0426BBFA-E307-4F0E-AC53-CF3A95D30F92Q43019633-1A6E8231-1770-490D-933D-3BA239E7FCD8Q44925317-2AE9F55C-4B4B-4E59-96C8-47FF00EE6E18Q44973290-0428B228-8749-493E-B2EA-D01355DF6C55Q47740893-72C1F785-8A93-4469-A001-619827B33BECQ47878961-EDD25EC3-CCA5-4D8B-B453-5F5F8D712ECAQ48016196-95B5EC1C-D056-425F-B4CF-66A7F7068301Q48224077-9EA0C1EE-E664-41A9-B955-8F2A6F5BD6FBQ48687384-A894B41A-33E6-49E8-97D4-904264269B2AQ58828834-1DA70E72-E59F-4D56-9D3B-15272A259F73
P2860
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Consensus proposals for the pr ...... high-emetic-risk chemotherapy.
@ast
Consensus proposals for the pr ...... high-emetic-risk chemotherapy.
@en
type
label
Consensus proposals for the pr ...... high-emetic-risk chemotherapy.
@ast
Consensus proposals for the pr ...... high-emetic-risk chemotherapy.
@en
prefLabel
Consensus proposals for the pr ...... high-emetic-risk chemotherapy.
@ast
Consensus proposals for the pr ...... high-emetic-risk chemotherapy.
@en
P2093
P2860
P1476
Consensus proposals for the pr ...... high-emetic-risk chemotherapy
@en
P2093
Cynthia Rittenberg
Enzo Ballatori
Jim Koeller
Jorn Herrstedt
Lawrence H Einhorn
Paul J Hesketh
Steven Grunberg
Sussanne Borjeson
P2860
P2888
P356
10.1007/S00520-004-0699-X
P50
P577
2004-11-23T00:00:00Z